RIFAMPICIN

Brand name:

• Rimycin 150®
• Rimycin 300®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Mylan

Condition/indication:
(therapeutic use)

• For the treatment of mycobacterium ulcerans infections (Buruli ulcer)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Minor Submission)

Comment:

--

Other PBAC consideration:

• RIFAMPICIN

Submission received for:

September 2020 PBAC meeting

Opportunity for consumer comment:

Open 29/04/2020 and close 10/06/2020 (see PBS Website)

PBAC meeting:

Held on 04/09/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

Exception applied

Lodgement of required documentation:

21/09/2020

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 28/09/2020

Status:

Finalised

Government processes:

Commenced on 27/10/2020

Medicine listed on the PBS:

01/12/2020 (see PBS schedule)